"Eribulin mesylate (Halaven, Eisai Inc.) has been approved by the US Food and Drug Administration (FDA) for use in the treatment of liposarcomas. This is the first drug to show an improvement in overall survival in this disease, the agenc"...
Xgeva may cause fetal harm when administered to a pregnant woman. In utero denosumab exposure in cynomolgus monkeys resulted in increased fetal loss, stillbirths, and postnatal mortality, along with evidence of absent lymph nodes, abnormal bone growth and decreased neonatal growth. Xgeva is contraindicated in women who are pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations].
Xgeva is contraindicated in patients with a history of systemic hypersensitivity to any component of the product. Reactions have included anaphylaxis, facial swelling and urticaria [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS].This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/30/2016
Additional Xgeva Information
Xgeva - User Reviews
Xgeva User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.